AOD-9604
Also known as: Fragment 177-191, hGH fragment
Growth hormone fragment that promotes fat loss through lipolysis without affecting IGF-1 or glucose.
Benefits
6
Conditions
5
Evidence
Strong preclinical evidence, limited human efficacy data+ studies
Source
Synthetic hGH fragment (amino acids 177-191)
Gabriel Brain Score
Moderate
Overview
Growth hormone fragment that promotes fat loss through lipolysis without affecting IGF-1 or glucose.
Mechanism of Action
Binds beta-3 adrenergic receptors on adipocytes, increases cAMP/PKA signaling, activates hormone-sensitive lipase for lipolysis, inhibits lipogenic enzymes, no GH receptor binding (no IGF-1 elevation), preferentially accumulates in adipose tissue.
Key Benefits
- ✓Promotes fat breakdown (lipolysis)
- ✓Inhibits new fat formation (lipogenesis)
- ✓Reduces body fat without affecting lean mass
- ✓No effect on blood glucose or insulin
- ✓Targets visceral and subcutaneous fat
- ✓May support cartilage repair
Clinical Applications
Dosing Guidelines
Subcutaneous injection
* Dosing should be individualized. Always consult with a qualified healthcare practitioner.
Research & Evidence
Strong preclinical evidence, limited human efficacy data
Excellent safety profile in human trials. Animal studies show significant fat loss. Human trials have not consistently demonstrated weight loss despite good safety. Mechanisms well-characterized in preclinical models.
Safety Information
Potential Side Effects
- •Minimal
- •Injection site reactions
- •Headache (rare)
Contraindications
- Pregnancy
- Breastfeeding
Interactions
- ⚠None well-documented
Quick Facts
Related Peptides
Retatrutide
Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors for maximal metabolic benefit and weight loss.
Tirzepatide
Dual GIP and GLP-1 receptor agonist that produces superior weight loss and glycemic control compared to GLP-1 agonists alone.
Semaglutide
Long-acting GLP-1 receptor agonist that reduces appetite, improves glycemic control, and promotes significant weight loss.